Published in Blood on April 14, 2016
Precision monitoring takes the stage. Blood (2016) 0.75
Haematological cancer: Staging and restaging patients with lymphoma - a better approach? Nat Rev Clin Oncol (2017) 0.75
Computed tomography--an increasing source of radiation exposure. N Engl J Med (2007) 41.06
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res (2001) 5.45
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med (2014) 4.98
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res (1977) 4.59
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol (2010) 3.38
[Not Available]. C R Seances Soc Biol Fil (1948) 3.32
Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. N Engl J Med (1983) 2.96
Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol (2014) 2.85
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol (2015) 2.64
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med (2015) 2.42
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). J Clin Oncol (2015) 2.15
Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem (2014) 1.78
Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol (2013) 1.73
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood (2015) 1.59
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia (2013) 1.52
Toward understanding and exploiting tumor heterogeneity. Nat Med (2015) 1.51
Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission. J Clin Oncol (2015) 1.47
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clin Cancer Res (2015) 1.29
Circulating cell free DNA: Preanalytical considerations. Clin Chim Acta (2013) 1.16
Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol (2013) 1.12
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Ann Oncol (2009) 1.03
Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer (2013) 1.00
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. Lancet Haematol (2014) 0.99
Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis. Br J Haematol (2015) 0.98
Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A (2015) 0.98
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Clin Cancer Res (2014) 0.96
Rearranged Ig heavy chain DNA is detectable in cell-free blood samples of patients with B-cell neoplasia. Blood (1997) 0.96
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood (2013) 0.95
A novel blood collection device stabilizes cell-free RNA in blood during sample shipping and storage. BMC Res Notes (2013) 0.90
Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis. Haematologica (2015) 0.82
Liquid biopsies reveal the dynamic nature of resistance mechanisms in solid tumors. Nat Med (2015) 0.78
A roadmap for discovery and translation in lymphoma. Blood (2015) 0.79
HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B cell receptor signaling. Blood (2016) 0.75
Cracking the diverse biologic code of diffuse large B-cell lymphoma. Semin Hematol (2015) 0.75
Precision monitoring takes the stage. Blood (2016) 0.75